|
|
6. Lutte contre les cancers
|
|
|
Types of translational research [The Incidental Economist]
|
|
|
|
|
|
“The
first roadblock (T1) was described by the roundtable as ‘the transfer
of new understandings of disease mechanisms gained in the laboratory
into the development of new methods for diagnosis, therapy, and
prevention and their first testing in humans.’ The roundtable described
the second roadblock (T2) as ‘the translation of results from clinical
studies into everyday clinical practice and health decision making.'”
|
|
|
|
|
|
|
|
New molecular pathology network for precision medicine [PHG Foundation]
|
|
|
|
|
|
“This
£16 million investment will enhance our UK-wide capability to deliver
21st Century diagnostics and complement initiatives such as the
Precision Medicine Catapult Centre to make sure that ground-breaking
medicines and technologies are adopted by the NHS and delivered to
patients as quickly as possible”.
|
|
|
|
|
|
|
|
|
Cancer Core Europe [Cancer World]
|
|
|
|
|
|
Can
deep and close-knit collaboration between a handful of elite centres
achieve what broader European research platforms and projects cannot?
|
|
|
|
|
|
|
6.1 Observation
|
|
|
NHS England must act as patients miss out on cancer drug tests [Cancer Research UK]
|
|
|
|
|
|
Our
report suggests that, in 2014, around 16,000 patients with lung and
bowel cancer in England missed out on these tests completely. Given what
we know about how often patients’ tests indicate they’re eligible for
targeted treatments, that means around 3,500 of these patients could
have been eligible for a targeted drug that may have helped them.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In
an era when there has been so much study of how to treat more advanced
cancer, it might seem odd that there is so much uncertainty about these
minute sprinklings of abnormal cells, often called Stage 0 cancer, which
some say are not cancers at all.
|
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
|
|
|
England’s new cancer strategy – what happens next? [Cancer Research UK]
|
|
|
|
|
|
There
are a lot of challenges ahead, but there are two crucial things that
need to happen. First, the organisations that lead the health service
need to develop clear, detailed plans for putting the Taskforce’s
recommendations into practice. And second, the Government needs to
invest the money to make it happen.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
|
6.6 Publications
|
|
|
|
1.5 Million ORCID iDs Served! [ORCID]
|
|
|
|
|
|
Our
technical team has been busy, launching peer review acknowledgements
and an updated API and, coming later this year, support for federated
login. We are also pleased to see the community using our record update
API, and are looking forward to launches soon by CrossRef and DataCite
that will automatically update ORCID records with published papers and
datasets for which the author included their ORCID iD.
|
|
|
|
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|
An Irresponsible Statement About Curing Cancer [In the Pipeline]
|
|
|
|
|
|
Look
at the case of Oliver Sacks: here is an extremely competent and acute
physician, but the first diagnosis he had of liver cancer was when it
was already metastatic. Not much we can do about that. Without better
diagnostics, it's hard to see how we're going to achieve really
impressive cure rates.
|
|
|
|
|
|
|
|
|
|
|
|